CERT

Based on Certara, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Certara do?

Certara provides biosimulation software and related services that help pharmaceutical and biotech companies model drug behavior during discovery, development, and regulatory review. Its platforms reduce the time and cost of bringing new medicines to market by enabling virtual trials and regulatory-grade modeling.

Does CERT pay dividends?

No, Certara does not currently pay a dividend. The company reinvests available capital into its software platform and service capabilities rather than returning cash to shareholders through distributions.

When does CERT report earnings?

Certara reports on a quarterly cadence like most US-listed companies. For exact dates and upcoming earnings schedules, check the investor relations section of Certara's official website.

Is CERT a good stock to buy?

UQS Score rates CERT as Below Average overall. While the Risk pillar is rated Good and Valuation is Attractive, the Quality, Moat, and Growth pillars all register as Weak. Investors should weigh these signals carefully. The full pillar breakdown is available to Pro members on UQS Score.

Is CERT overvalued?

Based on the UQS Valuation pillar, CERT is rated Attractive — suggesting the stock may be trading at a discount relative to its fundamental profile. That said, an attractive price alone does not offset the weaknesses visible in other pillars.

How does CERT compare to its competitors?

Certara occupies a specialized niche in biosimulation software and regulatory services. Peers like Schrödinger approach drug discovery from a physics-based computational angle, while Teladoc and Omada Health operate in patient-facing digital health — a different market segment entirely.

What is CERT's market cap bracket?

Certara is classified as a small-cap company. This places it in a segment where liquidity, analyst coverage, and institutional ownership can be more limited than for large- or mega-cap peers in the healthcare technology space.

Who founded Certara?

Certara was founded in 2008. Detailed founding history, including leadership origins, is publicly available through the company's official website and regulatory filings.

Is CERT a long-term quality indicator?

As a long-term quality indicator, CERT's UQS profile raises some caution. The Weak ratings across Quality, Moat, and Growth suggest the company has not yet demonstrated the durable competitive advantages and consistent financial performance that typically support long-term compounding. The Good Risk rating provides some stability context.

What is the main competitive advantage of Certara?

Certara's positioning in regulatory-grade biosimulation — where its software is embedded in drug submission workflows — creates a degree of customer stickiness. However, the UQS Moat pillar currently rates this advantage as Weak, indicating the competitive edge may not yet be sufficiently durable or wide.

What sector does CERT belong to?

Certara operates in the Healthcare sector, specifically at the intersection of pharmaceutical technology and software. It serves biopharmaceutical companies and research institutions rather than delivering direct patient care.

Is CERT a growth stock or value stock?

Based on UQS pillar labels, CERT presents a mixed picture. The Growth pillar is rated Weak, which limits its classification as a pure growth play. The Valuation pillar is Attractive, adding a value-oriented dimension — though this combination warrants careful analysis rather than a simple label.

Certara, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Certara, Inc. faces growth headwinds with declining or stagnant revenue trends.

Certara, Inc. maintains a reasonable risk profile with manageable debt levels.

Certara, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Certara, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CERT.

The UQS (Unified Quality Score) for Certara, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Certara, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Certara, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.